Ipratropium bromide/salbutamol

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ipratropium bromide/salbutamol
Combination of
Ipratropium bromide Muscarinic antagonist
Salbutamol Short-acting β2-adrenergic agonist
Clinical data
Pregnancy cat.
Legal status
Routes Inhalation
Identifiers
ATC code R03AK04
ChemSpider 21106326 YesY
 YesY (what is this?)  (verify)

The combination preparation ipratropium bromide/salbutamol is a formulation containing ipratropium bromide and salbutamol sulfate (albuterol sulfate) used in the management of chronic obstructive pulmonary disease (COPD) and asthma (not an FDA approved usage).[2] It is marketed by Boehringer Ingelheim as a metered dose inhaler (MDI) and nebuliser under the trade name Combivent. It is also marketed by Dey, L.P. (Napa, California) under the brand name DuoNeb as a nebulizer. In Italy it is known as Breva. The chemical is sold in India by Cipla as duolin. [3]

Since Combivent contains a chlorofluorocarbon based propellant, it is being phased out in European Union countries. Chloroflourocarbons (CFC) are attributed to depletion of the ozone layer.

DuoNeb controversy[edit]

DuoNeb has been a subject of a recent Medicare and U.S. Food and Drug Administration (FDA) controversy. FDA has moved for the regulation of generic competition for commercial products. Medicare has moved to limit the reimbursement of commercial products. Dispute resolution will have an economic impact on leading respiratory service providers, as well as patients.[citation needed]

External links[edit]

References[edit]

  1. ^ http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Combivent+IA/combivent.pdf
  2. ^ "Expert Panel 3. Expert panel report 3: guidelines for the diagnosis and management of asthma.". ): National Institutes of Health. National Heart, Lung, and Blood Institute. 2007. 
  3. ^ http://www.cipladoc.com/therapeutic/admin.php?mode=prod&action=disp&id=240
  • National Asthma Education and Prevention Program Expert Panel 3. Expert panel report 3: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health. National Heart, Lung, and Blood Institute; 2007 Aug. NIH Publication No. 07-4051.